Can Test Reports for Active Medical Devices Be Reused for Overseas Registration?

Whether test reports for active medical devices can be reused for overseas registration cannot be answered with a simple yes or no. Companies should first determine whether the target country regulates the product as a medical device, confirm the product classification and risk class, and then identify the registration pathway and the applicant entity. In general, electrical safety, EMC, and performance test reports obtained under the NMPA, CE, or FDA frameworks can be reused as core technical evidence provided the test standards align with the target country's requirements, the reports remain within their validity period, and they are issued by a competent laboratory. However, markets such as GHWP member states, Southeast Asia, the Middle East, and Latin America often require localization, including updated standard versions, local-language labeling and instructions for use, local agent or authorized representative documentation, and additional data for local populations and clinical environments. To avoid registration delays and deficiency risks, test reports should be assessed within the overall technical file, using a structured five-step process: classification decision, standards comparison, qualification confirmation, supplementary documentation, and localization adaptation.

Note: This FAQ is compiled from the AIMEILI Registration Practice Database, the Medical Device International Registration Knowledge Base, and publicly available regulatory information. For specific projects, always refer to the latest requirements of the target country's regulatory authority and the product documentation.

Executive Summary

Markets such as GHWP member states, Southeast Asia, the Middle East, and Latin America often require localization, including updated standard versions, local-language labels and instructions, local agent or authorized representative documentation, and additional data for local populations and clinical environments. When reusing reports, companies must also check whether supporting documents such as quality system certificates, risk management reports, clinical evaluations or clinical evidence, and post-market maintenance plans remain valid.

The reuse of test reports should be considered within the entire technical documentation. Companies should advance according to the five-step process of classification decision, standards comparison, qualification confirmation, documentation supplementation, and localization adaptation. This minimizes the risk of registration delays and deficiency requests caused by unavailable or non-compliant reports.

Applicable Scenarios and Core Questions

When registering active medical devices overseas, companies often ask whether test reports prepared for a previous market can be submitted directly to the new market. This question reflects concerns about registration cost and timeline control, but an accurate answer requires an understanding of the role and status of test reports in the registration file.

Test reports generally fall into two categories. The first covers product safety and performance tests, such as electrical safety, electromagnetic compatibility, environmental testing, and biocompatibility. The second covers product performance verification and software validation. Acceptance of these evidence types varies among countries; therefore, a simple 'reusable' or 'not reusable' judgment is not appropriate.

Core questions include: Does the target country require local laboratory testing? Is the standard version referenced in the report still recognized locally? Does the issuing laboratory hold the necessary local or international accreditation? Is the report subject to a validity period? Companies should evaluate these specific questions rather than assuming all reports can be reused.

In practice, active devices, because of their structural complexity and higher safety risk, undergo more rigorous regulatory review than passive products. Consequently, the association between test reports and device risk is closely examined.

Registration Judgment Logic

Step 1: Determine the product's regulatory scope in the target country. Some products that are regulated as medical devices by NMPA may fall under other categories in the destination country. This determination is based on each country's legal definitions and classification rules.

Step 2: Confirm the risk class and registration pathway. Active medical devices typically correspond to higher risk classes, such as Class II or Class III under U.S. FDA, Class IIa or higher under EU MDR, and various classifications across Southeast Asian jurisdictions. The risk class directly affects the required test items and documentary requirements.

Step 3: Assess the alignment of technical standards. If the target country adopts IEC 60601 series standards and the report version is consistent with local regulations, the core test reports may be reused. If the standard version differs or the country has special requirements, supplementary testing will be necessary.

Step 4: Verify the issuing laboratory's qualification. Some countries accept only reports issued by domestic or designated laboratories, while others accept reports from laboratories accredited to ISO/IEC 17025.

Step 5: Confirm report validity and quality system certification. Many countries require that test reports remain valid at the time of submission and that manufacturers hold a quality system certificate compliant with local regulations, such as ISO 13485, MDSAP, or an equivalent recognized system.

Step 6: Integrate labeling, local agent, authorized representative, and post-market maintenance requirements. A test report is only one component of the technical file and cannot be evaluated in isolation.

Documentation and Evidence

Reusable documents include: electrical safety test reports compliant with IEC 60601-series standards, electromagnetic compatibility test reports, usability engineering reports, risk management reports (ISO 14971), and certain performance verification reports.

Documents requiring careful evaluation include: performance tests conducted for a specific market, such as data required by certain countries from local clinical institutions; biocompatibility reports, because different markets may adopt different versions of ISO 10993; and software validation reports, especially if algorithms or user interfaces have been adapted for local markets.

Documents that must be localized include: labels and instructions for use, which must be translated into the target country's language and comply with local formats; local agent or authorized representative documentation; power plug, voltage, and frequency adaptation testing; and special tests such as wireless device certification for the U.S. FCC or Canada's ISED.

Quality system documents can generally be reused as foundational evidence, but companies should verify the certificate scope, manufacturing addresses, and traceability in the target country.

We recommend creating an evidence mapping table that matches each registration requirement to existing test reports, technical documents, and quality system certificates, allowing companies to identify gaps and risk points.

Common Mistakes

Below are the most common errors that occur when reusing test reports, which can lead to application rejection or deficiency requests:

• Submitting outdated reports without comparing standard versions, requiring local reviewers to request supplementation or retesting.
• Assuming an ISO 13485 certificate covers all markets and ignoring U.S. FDA QSR 820 or MDSAP requirements.
• Overlooking report validity periods, including submitting reports that have expired or do not meet local validity requirements.
• Ignoring local restrictions on laboratory qualifications; for example, some countries accept only reports issued by domestic laboratories.
• Failing to prepare local agent documents, authorized representative files, or labeling, causing submission blocking.
• Focusing only on test reports while ignoring updates to risk management, clinical evaluation, and other supporting documents.
• Lacking centralized technical file management in multi-country registrations, leading to inconsistent versions across markets.
• Not establishing post-market surveillance and adverse event reporting procedures according to target country requirements, creating renewal risks.

Company Preparation Checklist

Companies can work through the following nine items to ensure the compliance and completeness of reused test reports:

• Verify the product classification and the target country's regulatory requirements to determine the registration pathway.
• List all existing test reports, noting standard version, issue date, validity period, and laboratory qualification.
• Compare the target country's technical standards with the standards in existing reports to identify needed supplementary testing.
• Confirm the scope and validity of quality system certificates, scheduling audits if necessary.
• Prepare labeling and instructions for use in the required local language and format.
• Appoint a qualified local agent or authorized representative and execute compliant documents.
• Compile risk management reports, clinical evaluations, or clinical evidence that align with the test reports.
• Establish post-market maintenance processes, including adverse event reporting, change notifications, and annual updates.
• For multi-country registrations in GHWP member states, Southeast Asia, the Middle East, and Latin America, create a centralized technical file library and a differentiated management plan.

AIMEILI Perspective

The most common misjudgment is the belief that 'if my report is from CE or FDA, other countries should also accept it.' In fact, every country has its own independent regulatory system and review standards. The reuse of test reports is possible only when the standards are aligned, the qualifications are valid, and the supporting documentation is complete.

A gap analysis should be performed at the outset rather than assembling documents from a template. We recommend that companies conduct a comprehensive technical documentation compliance review before starting overseas registration. This review should identify which reports can be reused directly, which require retesting, and which must be localized, thereby avoiding repeated deficiency requests during review and saving considerable time.

Which documents can be reused? Test reports that meet international standards and are still valid, risk management documents, certain performance verification reports, and quality system certificates. Which documents must be localized? Labels and instructions for use, local agent files, power supply adaptation test data, clinical or performance data generated for the local market, and special certificates required by local regulations.

Local agent and certificate control are highly important. Many countries require foreign manufacturers to designate a local agent or authorized representative and file the registration in that entity's name. The registration certificate is usually held by the local agent or representative. If the agent changes or responsibilities are unclear, the registration certificate may become invalid. Therefore, companies should clearly define certificate ownership, change notification, and renewal responsibilities in their cooperation agreements.

For multi-country registrations, we recommend implementing a centralized technical document database with unified version control for test reports, risk management files, quality system certificates, and other core documents. Every update should be synchronized across all markets, and local differences should be evaluated by professional regulatory consultants. This approach greatly reduces the burden of recompiling documents and the risk of deficiency requests.

Frequently Asked Questions

Do test reports have a validity period? Is it the same across countries?

Most test reports do not have an absolute validity period, but some countries require that reports be issued within the last three or five years, or that the standards referenced in the report remain effective at the time of application. For example, certain Southeast Asian countries limit acceptance to reports issued within the last three years. Companies should confirm the specific requirements in the target market and plan for retesting accordingly.

Can test reports from NMPA registration be directly reused for EU MDR registration?

If the standards used in the reports are consistent with the EU harmonized standards and the laboratory holds appropriate qualifications, core electrical safety and EMC reports can be used as part of the MDR technical documentation. However, additional documents will be required, including clinical evaluation, updated risk management information, and the appointment of an EU authorized representative.

Can the same report be used for registration in multiple countries simultaneously?

Yes, provided that each country accepts the report, the standards versions are consistent, and the supporting documentation for each country does not conflict. For multi-country registration, it is advisable to centrally manage the originals and translations of reports to avoid version confusion.

What should we do if the target country requires local testing?

Some countries, for reasons of domestic industry protection or safety oversight, require active medical devices to be tested in a national or recognized laboratory. In such cases, companies must send samples for local testing, but they can use technical data and test methods from existing reports to reduce duplication of validation work.

Content Review and Applicability Boundary

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulations; industry media and project experience are used only as supplementary reference.

Publication date: August 10, 2026. Update date: August 10, 2026.

Applicability boundary: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the official requirements of the target country's regulatory authority, test conclusions, or legal advice.